Overview

IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients

Status:
Completed

Trial end date:
2017-12-22

Target enrollment:

Participant gender:

Summary

This study will establish whether intravenous iron replacement has clinical benefit in idiopathic pulmonary arterial hypertension. A 24-week double-blind, randomised, placebo-controlled, crossover study will investigate whether a single dose of 1g of Ferinject® or CosmoFer improves cardiopulmonary haemodynamics, exercise capacity and quality of life and is well-tolerated.

Phase:

Phase 2

Details

Lead Sponsor:

Imperial College London

Collaborator:

Fu Wai Hospital, Beijing, China

Treatments:

Iron